General Information of Drug (ID: DM3415L)

Drug Name
BAX-499 Drug Info
Synonyms ARC-19499; Tissue factor pathway inhibitor (hemophilia A/hemophilia B), Archemix
Indication
Disease Entry ICD 11 Status REF
Factor IX deficiency 3B11 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM3415L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tifacogin DMMO6P0 Sepsis 1G40-1G41 Phase 3 [3]
PF-06741086 DMW63TQ Hemophilia 3B10.0 Phase 3 [4]
Concizumab DM1BRWD Haemophilia A 3B10.0 Phase 3 [5]
NN-7415 DMHVIZC Factor IX deficiency 3B11 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tissue factor pathway inhibitor (TFPI) TT068JH TFPI1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01191372) First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients. U.S. National Institutes of Health.
2 Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45.
3 Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
4 Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46.
5 Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 Nov 28;134(22):1973-1982.
6 Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.J Thromb Haemost.2015 May;13(5):743-54.